Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis

Shunsuke Yamada, Kazuhiko Tsuruya, Masanori Tokumoto, Hisako Yoshida, Narihito Tatsumoto, Hiroaki Ooboshi, Takanari Kitazono

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

As fibroblast growth factor 23 (FGF23) has been shown to induce cardiovascular disease directly in patients with chronic kidney disease, identification of factors and treatments that can modulate serum FGF23 (sFGF23) level is clinically important. This retrospective longitudinal study investigated factors that modulate sFGF23 in 49 patients who underwent peritoneal dialysis (PD). sFGF23 ratio (sFGF23 at 18 months/baseline sFGF23) was used as an indicator of changes in sFGF23 level. Total phosphate elimination was the sum of both renal phosphate excretion and dialysate phosphate elimination. In multivariate analysis, log sFGF23 ratio was associated negatively with total phosphate elimination and the use of cinacalcet at baseline, and positively with the use of vitamin D receptor activators at baseline, even after adjusting for potential confounding factors. Our study indicates that maintaining phosphate elimination can prevent increased sFGF23, thereby preventing cardiovascular events in patients who undergo PD.

Original languageEnglish
Pages (from-to)71-78
Number of pages8
JournalTherapeutic Apheresis and Dialysis
Volume21
Issue number1
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Peritoneal Dialysis
Phosphates
Serum
Calcitriol Receptors
fibroblast growth factor 23
Dialysis Solutions
Chronic Renal Insufficiency
Longitudinal Studies
Cardiovascular Diseases
Multivariate Analysis
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis. / Yamada, Shunsuke; Tsuruya, Kazuhiko; Tokumoto, Masanori; Yoshida, Hisako; Tatsumoto, Narihito; Ooboshi, Hiroaki; Kitazono, Takanari.

In: Therapeutic Apheresis and Dialysis, Vol. 21, No. 1, 01.02.2017, p. 71-78.

Research output: Contribution to journalArticle

@article{f34b7e7a0b884b678cc4091a4508ff7a,
title = "Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis",
abstract = "As fibroblast growth factor 23 (FGF23) has been shown to induce cardiovascular disease directly in patients with chronic kidney disease, identification of factors and treatments that can modulate serum FGF23 (sFGF23) level is clinically important. This retrospective longitudinal study investigated factors that modulate sFGF23 in 49 patients who underwent peritoneal dialysis (PD). sFGF23 ratio (sFGF23 at 18 months/baseline sFGF23) was used as an indicator of changes in sFGF23 level. Total phosphate elimination was the sum of both renal phosphate excretion and dialysate phosphate elimination. In multivariate analysis, log sFGF23 ratio was associated negatively with total phosphate elimination and the use of cinacalcet at baseline, and positively with the use of vitamin D receptor activators at baseline, even after adjusting for potential confounding factors. Our study indicates that maintaining phosphate elimination can prevent increased sFGF23, thereby preventing cardiovascular events in patients who undergo PD.",
author = "Shunsuke Yamada and Kazuhiko Tsuruya and Masanori Tokumoto and Hisako Yoshida and Narihito Tatsumoto and Hiroaki Ooboshi and Takanari Kitazono",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/1744-9987.12478",
language = "English",
volume = "21",
pages = "71--78",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis

AU - Yamada, Shunsuke

AU - Tsuruya, Kazuhiko

AU - Tokumoto, Masanori

AU - Yoshida, Hisako

AU - Tatsumoto, Narihito

AU - Ooboshi, Hiroaki

AU - Kitazono, Takanari

PY - 2017/2/1

Y1 - 2017/2/1

N2 - As fibroblast growth factor 23 (FGF23) has been shown to induce cardiovascular disease directly in patients with chronic kidney disease, identification of factors and treatments that can modulate serum FGF23 (sFGF23) level is clinically important. This retrospective longitudinal study investigated factors that modulate sFGF23 in 49 patients who underwent peritoneal dialysis (PD). sFGF23 ratio (sFGF23 at 18 months/baseline sFGF23) was used as an indicator of changes in sFGF23 level. Total phosphate elimination was the sum of both renal phosphate excretion and dialysate phosphate elimination. In multivariate analysis, log sFGF23 ratio was associated negatively with total phosphate elimination and the use of cinacalcet at baseline, and positively with the use of vitamin D receptor activators at baseline, even after adjusting for potential confounding factors. Our study indicates that maintaining phosphate elimination can prevent increased sFGF23, thereby preventing cardiovascular events in patients who undergo PD.

AB - As fibroblast growth factor 23 (FGF23) has been shown to induce cardiovascular disease directly in patients with chronic kidney disease, identification of factors and treatments that can modulate serum FGF23 (sFGF23) level is clinically important. This retrospective longitudinal study investigated factors that modulate sFGF23 in 49 patients who underwent peritoneal dialysis (PD). sFGF23 ratio (sFGF23 at 18 months/baseline sFGF23) was used as an indicator of changes in sFGF23 level. Total phosphate elimination was the sum of both renal phosphate excretion and dialysate phosphate elimination. In multivariate analysis, log sFGF23 ratio was associated negatively with total phosphate elimination and the use of cinacalcet at baseline, and positively with the use of vitamin D receptor activators at baseline, even after adjusting for potential confounding factors. Our study indicates that maintaining phosphate elimination can prevent increased sFGF23, thereby preventing cardiovascular events in patients who undergo PD.

UR - http://www.scopus.com/inward/record.url?scp=85011556581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011556581&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12478

DO - 10.1111/1744-9987.12478

M3 - Article

C2 - 28078749

AN - SCOPUS:85011556581

VL - 21

SP - 71

EP - 78

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 1

ER -